Shares of Hims & Hers Health are lower as the market digests a tougher competitive landscape in GLP-1 weight management following Amazon’s national push through One Medical, paired with Amazon Pharmacy fulfillment and clearer cash-pay pricing. That entry raises concerns that large-scale platforms with embedded logistics and broader healthcare touchpoints could siphon demand or force higher marketing spend across telehealth incumbents.

Hims has leaned into weight management as a major growth driver, but the category is increasingly crowded and sensitive to customer acquisition costs, drug availability, and payer dynamics. Amazon’s approach—positioning GLP-1 treatment inside a broader primary-care model—could shift consumer expectations toward more longitudinal care, potentially challenging fast-onboarding telehealth models and pressuring margins if Hims must spend more to retain or win subscribers.

The move is also occurring with Hims’ next earnings date approaching on May 11, 2026, which can amplify day-to-day volatility as investors adjust exposure. Traders are likely looking for commentary on weight-loss demand trends, churn, and the profitability impact of investments in infrastructure (including labs and supply chain capabilities) versus the need to keep pricing competitive.

Key read-throughs include whether Hims reports resilience in weight-management enrollment despite new mega-cap entrants, any updates on the mix between FDA-approved GLP-1 access versus compounded alternatives, and whether management signals changes to 2026 expectations. Any evidence of accelerating competition-driven customer acquisition costs or slower GLP-1 momentum could keep pressure on the shares into and through the earnings event.